Michael J. Keating

96.0k citations
1.1k papers · 66.8k · 20 hit papers · h-index 121

Impact in

  • Genetics top 0.01%
    • Chronic Lymphocytic Leukemia Research
  • Hematology top 0.01%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation

Papers in

Michael J. Keating

1.1k papers receiving 64.9k citations

Michael J. Keating's Hit Papers

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL 2018 · 1.0k citations
1.0k0+8+17Years since publication10002.0k3.0k

Peers

Michael J. Keating
Comparison fields: 5 of 201
  • Genetics 29.0k
  • Hematology 19.3k
  • Pathology and Forensic Medicine 17.8k
  • Immunology 12.6k
  • Oncology 11.5k
Replace Hartmut Döhner with:
Hartmut Döhner Germany
Donna Neuberg United States
Michael Andreeff United States
Brian Druker United States
Kenneth C. Anderson United States
Irving L. Weissman United States
Benjamin L. Ebert United States
Guillermo Garcia‐Manero United States
Stuart H. Orkin United States
Charles L. Sawyers United States
Michael J. Keating relative to Hartmut Döhner Germany Hartmut Döhner's profile →
Citations per field
00.5×1.5×1.8×
Hartmut Döhner · 1×
Citations per year

Countries citing papers authored by Michael J. Keating

Since Specialization
Citations

This map shows the geographic impact of Michael J. Keating's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Keating with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Keating more than expected).

Fields of papers citing papers by Michael J. Keating

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Keating. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Keating. The network helps show where Michael J. Keating may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael J. Keating, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Keating Line = papers co-authored together Michael J. Keating links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 1.1k papers — load more, or switch the sort, to bring in the rest.

#Work
1
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
Hit paper breakdown →
20023880
2
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Hit paper breakdown →
20082214
3
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Hit paper breakdown →
20181002
4
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Hit paper breakdown →
1997907
5
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Hit paper breakdown →
2011797
6
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Hit paper breakdown →
1998737
7
Superoxide dismutase as a target for the selective killing of cancer cells
Hit paper breakdown →
2000726
8
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Hit paper breakdown →
2002709
9
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Hit paper breakdown →
2005705
10
Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia
Hit paper breakdown →
2005703
11
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
Hit paper breakdown →
2004657
12
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
Hit paper breakdown →
1990621
13
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Hit paper breakdown →
2000592
14
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Hit paper breakdown →
2000561
15
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Hit paper breakdown →
2008509
16
Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic Syndromes
Hit paper breakdown →
1987509
17 2011498
18
Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous Leukemia
Hit paper breakdown →
1986488
19 2001468
20 2004461

About Michael J. Keating

Michael J. Keating is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Molecular Biology and Immunology, having authored 1.1k papers that have together received 66.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (640 papers), Lymphoma Diagnosis and Treatment (309 papers), Acute Myeloid Leukemia Research (199 papers), Acute Lymphoblastic Leukemia research (186 papers), Immunodeficiency and Autoimmune Disorders (158 papers), Chronic Myeloid Leukemia Treatments (124 papers), Neutropenia and Cancer Infections (46 papers) and Advanced Breast Cancer Therapies (40 papers). The work is most often cited by research in Genetics (29.0k citations), Hematology (19.3k citations), Pathology and Forensic Medicine (17.8k citations), Immunology (12.6k citations) and Oncology (11.5k citations). Michael J. Keating has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Hagop M. Kantarjian, Susan O’Brien, William G. Wierda, Emil J. Freireich, William Plunkett, Elihu H. Estey, Jörge E. Cortes, Francis J. Giles, Susan Lerner and Maher Albitar. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Leukemia and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact